Profarma Distribuidora de Produtos Farmaceuticos SA
BOVESPA:PFRM3

Watchlist Manager
Profarma Distribuidora de Produtos Farmaceuticos SA Logo
Profarma Distribuidora de Produtos Farmaceuticos SA
BOVESPA:PFRM3
Watchlist
Price: 8.6 BRL 3.12% Market Closed
Market Cap: R$1.1B

Intrinsic Value

The intrinsic value for Profarma Distribuidora de Produtos Farmaceuticos SA (PFRM3) under the Base Case is 24.28 BRL. Compared with the current market price of 8.6 BRL, the stock appears Undervalued by 65%.

Based on two methods:

Both DCF and multiples point to undervaluation.

PFRM3 Intrinsic Value
24.28 BRL
Undervaluation 65%
Intrinsic Value
Price R$8.6
Worst Case
Base Case
Best Case
Get notified when the price drop
Track Buy Zone
20% below Intrinsic Value R$19.43
Get notified when the price drops into your buy zone
Intrinsic Value R$24.28
Margin of Safety 20% R$19.43
Current Price R$8.6
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about PFRM3?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is PFRM3 valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Profarma Distribuidora de Produtos Farmaceuticos SA.

Explain Valuation
Alternatives to PFRM3

Wall St
Price Targets

Dividends

Shareholder Yield

Competitive Landscape

What is the Intrinsic Value of one PFRM3 stock?

The intrinsic value for Profarma Distribuidora de Produtos Farmaceuticos SA (PFRM3) under the Base Case is 24.28 BRL.

Is PFRM3 stock undervalued or overvalued?

Compared with the current market price of 8.6 BRL, the stock appears Undervalued by 65%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett